| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Bastos, Paulo |
| dc.contributor.author | Mavromanolaki, Viktoria Eirini |
| dc.contributor.author | Maraki, Sofia |
| dc.contributor.author | Spiliopoulou, Anastasia |
| dc.contributor.author | Boattini, Matteo |
| dc.contributor.author | Bianco, Gabriele |
| dc.contributor.author | Larrosa-Garcia, Maria |
| dc.contributor.author | VIÑADO, BELEN |
| dc.date.accessioned | 2025-04-04T06:35:41Z |
| dc.date.available | 2025-04-04T06:35:41Z |
| dc.date.issued | 2025-06 |
| dc.identifier.citation | Boattini M, Bianco G, Bastos P, Mavromanolaki VE, Maraki S, Spiliopoulou A, et al. Diagnostic and epidemiological landscape of anaerobic bacteria in Europe, 2020-2023 (ANAEuROBE). Int J Antimicrob Agents. 2025 Jun;65(6):107478. |
| dc.identifier.issn | 0924-8579 |
| dc.identifier.uri | http://hdl.handle.net/11351/12895 |
| dc.description | Anaerobes; Antimicrobial resistance; Blood culture |
| dc.description.abstract | Introduction
Despite being implicated in a wide spectrum of community- and healthcare-acquired infections, anaerobes have not yet been incorporated into systematic surveillance programs in Europe.
Methods
We conducted a multicentre retrospective observational study analysing all anaerobic strains isolated from blood cultures in 44 European Hospital Centres over a 4-y period (2020–2023). Diagnostic approach, epidemiology, and antimicrobial susceptibility according to EUCAST v. 15.0 were investigated.
Results
Our study included 14,527 anaerobes, most of which were Gram-positive (45%) or Gram-negative (40%) bacilli. MALDI-TOF coupled to mass spectrometry was the most widely used tool for species identification (98%). Antimicrobial susceptibility testing was performed in the vast majority of centres, using mostly gradient diffusion strip (77%) and disk diffusion (45%) methods according to EUCAST guidelines. The most prevalent species were Cutibacterium acnes (18.7%), Bacteroides fragilis (16.3%), Clostridium perfringens (5.3%), Bacteroides thetaiotaomicron (4.2%), Fusobacterium nucleatum (3.5%), and Parvimonas micra (3.4%). C. acnes showed high resistance to benzylpenicillin (18%), clindamycin (39%), and imipenem (19% and 13% by MIC methods and disk diffusion, respectively). B. fragilis showed high resistance to amoxicillin/clavulanate (24%), piperacillin/tazobactam (22% and 14% by MIC methods and disk diffusion, respectively), clindamycin (22% by both MIC methods and disk diffusion), meropenem (13%), and metronidazole (10%, only by disk diffusion). A similar resistance pattern was observed in B. thetaiotaomicron, Bacteroides ovatus, and Parabacteroides distasonis. C. perfringens showed high resistance to clindamycin (69% and 45% by MIC methods and disk diffusion, respectively), while benzylpenicillin and metronidazole maintained over 90% activity. F. nucleatum showed high resistance to benzylpenicillin (11%), while Fusobacterium necrophorum showed alarming rates of resistance to clindamycin (12%), meropenem (16%) and metronidazole (11%).
Conclusions
This study presented an up-to-date analysis of the diagnostics and epidemiology of anaerobic bacteria in Europe, providing insights for future comparative analyses and the development of antimicrobial diagnostic and management strategies, as well as the optimization of current antibiotic treatments. |
| dc.language.iso | eng |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | International Journal of Antimicrobial Agents;65(6) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Microorganismes - Resistència als medicaments |
| dc.subject | Bacteris anaerobis |
| dc.subject | Malalties bacterianes gramnegatives - Diagnòstic |
| dc.subject.mesh | Bacteria, Anaerobic |
| dc.subject.mesh | Bacteroides Infections |
| dc.subject.mesh | /diagnosis |
| dc.subject.mesh | Drug Resistance, Microbial |
| dc.subject.mesh | Blood Culture |
| dc.title | Diagnostic and epidemiological landscape of anaerobic bacteria in Europe, 2020–2023 (ANAEuROBE) |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.ijantimicag.2025.107478 |
| dc.subject.decs | bacterias anaerobias |
| dc.subject.decs | infecciones por Bacteroides |
| dc.subject.decs | /diagnóstico |
| dc.subject.decs | farmacorresistencia microbiana |
| dc.subject.decs | hemocultivo |
| dc.relation.publishversion | https://doi.org/10.1016/j.ijantimicag.2025.107478 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Boattini M] Department of Public Health and Paediatrics, University of Torino, Turin, Italy. Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy. Lisbon Academic Medical Centre, Lisbon, Portugal. [Bianco G] Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy. Department of Experimental Medicine, University of Salento, Lecce, Italy. [Bastos P] Department of Medical and Clinical Pharmacology, Toulouse University Hospital, Toulouse, France. [Mavromanolaki VE] Department of Paediatrics, Agios Nikolaos General Hospital, Crete, Greece. [Maraki S] Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece. [Spiliopoulou A] Department of Microbiology, University of Patras, Medical School, Patras, Greece. [Larrosa Escartín MN, Viñado Perez MB] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain |
| dc.identifier.pmid | 40024606 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |